+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

mRNA Synthesis & Manufacturing Market by Services, Service Type, Manufacturing Process, Manufacturing Scale, Technology, Application, Usage, End-User - Global Forecast to 2030

  • PDF Icon

    Report

  • 189 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6021445
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

ThemRNA Synthesis & Manufacturing Market was valued at USD 2.71 billion in 2024 and is projected to grow to USD 2.96 billion in 2025, with a CAGR of 9.40%, reaching USD 4.65 billion by 2030.

Setting the Stage for mRNA Synthesis Evolution

Messenger RNA technology has emerged as a cornerstone of modern biotechnology, catalyzing breakthroughs in vaccines, therapeutics, and diagnostic tools. The synthesis and manufacturing of mRNA strands have evolved from niche research functions into robust production processes capable of meeting global demand. Advanced platforms now enable rapid design iterations and high-fidelity manufacturing, empowering developers to respond swiftly to emerging health threats and customize treatments. As industry stakeholders refine their technical capabilities, the mRNA segment has transcended traditional boundaries, forging partnerships across academia, contract development organizations, and large biopharma players. This convergence of expertise accelerates the transition from laboratory innovations to real-world clinical applications.

Against this backdrop, our executive summary delves into the transformative shifts defining mRNA manufacturing today. By examining recent technological leaps, regulatory milestones, and strategic market movements, we reveal the forces reshaping supply chains, cost structures, and product portfolios. This in-depth overview also assesses the implications of 2025 U.S. tariffs on the procurement of critical raw materials, offering clarity on the ensuing ripple effects. Fueled by specialized segmentation and regional analyses, our insights equip decision-makers with the knowledge needed to identify high-value opportunities, mitigate risk, and craft winning strategies in a rapidly evolving ecosystem.

Uncovering the Pivotal Forces Redefining mRNA Manufacturing

The past five years have witnessed pivotal innovations that redefine how mRNA molecules are conceptualized, synthesized, and delivered. Lipid nanoparticle technology has matured from experimental formulations to scalable delivery vehicles with tunable release profiles and tissue targeting. Concurrently, in silico design algorithms now integrate codon optimization, immunogenicity prediction, and secondary structure modeling to maximize translational efficiency and minimize off-target effects. These computational tools have cut development timelines, enabling candidates to progress from digital design to bench-scale transcription in a matter of weeks.

Regulatory frameworks have adapted in parallel, introducing adaptive review pathways and platform-based approvals that recognize shared safety and efficacy data across mRNA constructs. Strategic collaborations between biotechs and contract manufacturing organizations have unlocked capacity expansions, while investments in modular, single-use systems bolster agility and reduce cross-contamination risks. As digital twins and blockchain-enabled traceability gain traction, stakeholders can improve batch release certainty and regulatory compliance. These transformative shifts forge a landscape where rapid iteration, flexible scale-up, and data-driven decision-making converge to accelerate the mRNA revolution.

Assessing the 2025 US Tariff Ripple Effect on mRNA Supply Chains

The implementation of new U.S. tariffs in 2025 introduces a complex layer of cost and sourcing considerations for mRNA manufacturing. Tariffs applied to key substrates and nucleotides have elevated input costs, compelling manufacturers to reevaluate supplier contracts and explore alternative procurement strategies. In response, some organizations have accelerated the onshoring of critical supply lines, forging domestic partnerships to mitigate exposure to import duties. Others have consolidated orders to achieve volume discounts or leveraged free trade zones to buffer tariff impacts.

The tariffs also influence global supply chain dynamics, as regions outside the United States become more attractive for early-stage manufacturing operations and material processing. Strategic reshoring and diversification efforts aim to ensure continuity of supply for enzymes, capping analogues, and lipid precursors. Pricing models are under pressure to absorb higher production costs without compromising affordability or market access. These adjustments, driven by tariff-induced economic signals, underscore the importance of supply chain resilience and highlight the need for agile procurement policies that align with evolving trade regulations.

Deep Dive into mRNA Service and Market Segmentation Dynamics

The mRNA synthesis and manufacturing landscape is best understood through its multifaceted segmentation across services, processes, scales, technologies, applications, usage, and end-users. The service spectrum encompasses every stage from template DNA preparation through formulation and storage, ensuring a seamless continuum from design to delivery. Within service types, bespoke custom orders and off-the-shelf catalogs co-exist, enabling clients to choose precisely tailored constructs or standardized variants based on project demands. On the manufacturing front, advanced lipid nanoparticle formulation, enzymatic capping methodologies, in vitro transcription, polyadenylation, and purification techniques collectively define the backbone of production pipelines.

Manufacturing scale ranges from pilot and lab environments to full commercial operations, offering progressive capacity expansion options. Technology choices between in vitro and in vivo synthesis reflect trade-offs in speed, cost, and regulatory complexity. Applications span cutting-edge therapeutics addressing cancer, infectious diseases, and rare disorders to prophylactic and therapeutic vaccines designed for global immunization campaigns. Considerations of usage extend to both human and veterinary markets, each with distinct regulatory pathways and performance criteria. Finally, academic and research institutes collaborate with contract manufacturers and major pharmaceutical and biotechnology companies, with university labs and government bodies fueling discovery and early development. This comprehensive segmentation map enables stakeholders to pinpoint high-value niches and align resources with the areas of greatest market potential.

Regional Powerhouses Shaping the mRNA Manufacturing Landscape

Regional dynamics reveal distinct strengths and challenges shaping mRNA manufacturing. In the Americas, robust infrastructure and a supportive regulatory environment have fostered large-scale commercial operations alongside agile research hubs. North American centers lead in platform approvals and innovative delivery systems, while Latin American markets are increasingly exploring local fill-finish capabilities to expand vaccine access. Across Europe, Middle East, and Africa, collaborative consortiums leverage diverse academic networks and government support to advance local production, although harmonizing cross-border regulations remains an ongoing objective. Investment in regional centers of excellence is accelerating as stakeholders seek to reduce dependency on external suppliers and bolster pandemic preparedness.

Asia-Pacific stands out for its rapid capacity build-out, driven by strong government incentives and a growing contract manufacturing base. Advanced economies in the region are pioneering integration of automation and digital manufacturing tools, while emerging markets are scaling foundational capabilities. Cross-regional partnerships are on the rise, with Asia-Pacific entities forming joint ventures to export technologies to underserved markets. These distinct regional trajectories underscore the critical need for tailored strategies that account for local regulatory landscapes, infrastructure maturity, and collaborative frameworks.

Spotlight on Leading Innovators Driving mRNA Industry Advances

Leading companies have emerged as innovation catalysts, driving advancements in mRNA synthesis and manufacturing technologies. Established biopharma innovators have expanded their pipelines through platform licensing agreements and internal capacity expansions, setting new benchmarks for large-scale production. Specialized contract developers have distinguished themselves by offering integrated end-to-end services, from in silico design to clinical-grade batch release, while academic spin-outs contribute cutting-edge enzymatic and formulation breakthroughs that push performance limits.

Strategic partnerships between technology providers and pharmaceutical giants have accelerated commercialization timelines, enabling rapid scale-up of novel vaccine candidates. Some emerging players have disrupted traditional cost structures through continuous manufacturing approaches and single-use bioreactors, reducing turnaround times and contamination risks. Quality control and analytics companies are also stepping into the spotlight, delivering real-time process monitoring and digital solutions that enhance batch consistency and regulatory compliance. Collectively, these market leaders exemplify a new breed of collaborative ecosystem participants that balance deep technical expertise with flexible service models to meet the evolving demands of mRNA developers.

Strategic Imperatives for Navigating the mRNA Frontier

Industry leaders aiming to excel in the mRNA sphere should prioritize the integration of advanced lipid nanoparticle and enzymatic capping platforms to enhance delivery efficiency and stability. Strengthening end-to-end supply chain resilience through strategic sourcing, geographic diversification, and vendor partnerships will mitigate the impact of trade fluctuations and material shortages. Investing in digital manufacturing technologies, such as real-time analytics and process automation, can drive cost efficiencies and accelerate batch release timelines.

Forming collaborative alliances with academic research centers and regulatory agencies will facilitate knowledge exchange and streamline approval pathways. Organizations should also cultivate a specialized talent pipeline by offering targeted training programs in transcriptomics, bioengineering, and regulatory affairs. Embracing modular facility designs and flexible single-use systems will allow rapid capacity expansions in response to emerging needs. Finally, proactive engagement with policymakers to shape favorable trade and regulatory environments can secure long-term access to critical materials and foster sustained innovation momentum.

Robust Research Framework Underpinning mRNA Market Insights

This research integrates primary interviews with industry executives, technical directors, and regulatory experts, complemented by extensive secondary analysis of peer-reviewed literature, patent filings, and public company disclosures. Data validation was achieved through triangulation across multiple sources, ensuring comprehensive coverage of technological, regulatory, and market developments. Segmentation analysis was performed to delineate services, processes, scales, technologies, applications, usage patterns, and end-user cohorts, supporting granular insights into value chain dynamics.

Regional assessments draw on trade data, government policy reviews, and infrastructure mapping, while a dedicated section on U.S. tariffs synthesizes legislative documentation and economic impact studies. Leading company profiles stem from an evaluation of clinical pipelines, strategic partnerships, and capacity investments. Throughout, rigorous quality control protocols have been applied to verify accuracy and objectivity, providing stakeholders with a transparent and reproducible analytical foundation for strategic decision-making.

Bridging Insights to Action in mRNA Synthesis and Manufacturing

The convergence of advanced technologies, adaptive manufacturing platforms, and evolving regulatory paradigms has propelled mRNA synthesis and manufacturing into a new era of possibility. As cost pressures intensify and supply chain complexities deepen, organizations that embrace agile strategies, foster cross-sector collaborations, and invest in next-generation capabilities will secure competitive advantage. This summary distills the critical forces at play and surfaces actionable insights to guide informed decision-making.

From the macroeconomic effects of trade policy to the nuanced interplay of service segmentation and regional capacities, stakeholders now possess a cohesive view of the mRNA landscape. By aligning strategic investments with targeted market niches and leveraging collaborative innovation networks, industry participants can drive sustained growth and deliver on the promise of mRNA for diverse therapeutic and vaccine applications.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Services
    • Capping & Tailing
    • Formulation
    • In Silico Design
    • Modification & Optimization
    • Purification & Quality Control
    • Storage & Distribution
    • Template DNA Preparation
  • Service Type
    • Custom mRNA Synthesis
      • Client-Specific mRNA Orders
      • Tailored Research Specifications
    • Standard mRNA Production
      • Cataloged mRNA Variants
      • Off-the-Shelf mRNA Selections
  • Manufacturing Process
    • Advanced LNP Formulation Technology
    • Enzymatic Capping & Cap Analogues
    • Genetic Engineering & Codon Optimization
    • In Vitro Transcription
    • Plasmid DNA Template
    • Polyadenylation
    • RNA Purification Techniques
  • Manufacturing Scale
    • Commercial Scale
    • Lab Scale
    • Pilot Scale
  • Technology
    • In Vitro Synthesis
    • In Vivo Synthesis
  • Application
    • Therapeutics
      • Cancer
      • Infectious Diseases
      • Rare Diseases
    • Vaccines
      • Prophylactic Vaccines
      • Therapeutic Vaccines
  • Usage
    • Human Use
    • Veterinary Use
  • End-User
    • Academic & Research Institutes
      • Government Research Bodies
      • University Laboratories
    • Contract Manufacturing Organizations
    • Pharmaceutical & Biotechnology Companies
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories Limited
  • Bio-Synthesis Inc.
  • Creative Biogene
  • Creative Biolabs
  • Croyez Bioscience Co., Ltd.
  • Danaher Corporation
  • FUJIFILM Wako Pure Chemical Corporation
  • Genewiz by Azenta Life Sciences
  • GenScript Biotech Corporation
  • Jena Bioscience GmbH by Enzo Biochem Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • New England Biolabs, Inc.
  • PackGene Biotech, Inc.
  • Promega Corporation
  • Samsung Biologics Co., Ltd.
  • Sartorius AG
  • ST Pharm
  • System Biosciences, LLC
  • Takara Bio Inc.
  • Telesis Bio Inc.
  • Thermo Fisher Scientific Inc.
  • TriLink BioTechnologies LLC by Maravai Intermediate Holdings, LLC
  • WuXi Biologics (Cayman) Inc

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. mRNA Synthesis & Manufacturing Market, by Services
8.1. Introduction
8.2. Capping & Tailing
8.3. Formulation
8.4. In Silico Design
8.5. Modification & Optimization
8.6. Purification & Quality Control
8.7. Storage & Distribution
8.8. Template DNA Preparation
9. mRNA Synthesis & Manufacturing Market, by Service Type
9.1. Introduction
9.2. Custom mRNA Synthesis
9.2.1. Client-Specific mRNA Orders
9.2.2. Tailored Research Specifications
9.3. Standard mRNA Production
9.3.1. Cataloged mRNA Variants
9.3.2. Off-the-Shelf mRNA Selections
10. mRNA Synthesis & Manufacturing Market, by Manufacturing Process
10.1. Introduction
10.2. Advanced LNP Formulation Technology
10.3. Enzymatic Capping & Cap Analogues
10.4. Genetic Engineering & Codon Optimization
10.5. In Vitro Transcription
10.6. Plasmid DNA Template
10.7. Polyadenylation
10.8. RNA Purification Techniques
11. mRNA Synthesis & Manufacturing Market, by Manufacturing Scale
11.1. Introduction
11.2. Commercial Scale
11.3. Lab Scale
11.4. Pilot Scale
12. mRNA Synthesis & Manufacturing Market, by Technology
12.1. Introduction
12.2. In Vitro Synthesis
12.3. In Vivo Synthesis
13. mRNA Synthesis & Manufacturing Market, by Application
13.1. Introduction
13.2. Therapeutics
13.2.1. Cancer
13.2.2. Infectious Diseases
13.2.3. Rare Diseases
13.3. Vaccines
13.3.1. Prophylactic Vaccines
13.3.2. Therapeutic Vaccines
14. mRNA Synthesis & Manufacturing Market, by Usage
14.1. Introduction
14.2. Human Use
14.3. Veterinary Use
15. mRNA Synthesis & Manufacturing Market, by End-User
15.1. Introduction
15.2. Academic & Research Institutes
15.2.1. Government Research Bodies
15.2.2. University Laboratories
15.3. Contract Manufacturing Organizations
15.4. Pharmaceutical & Biotechnology Companies
16. Americas mRNA Synthesis & Manufacturing Market
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. Argentina
17. Europe, Middle East & Africa mRNA Synthesis & Manufacturing Market
17.1. Introduction
17.2. United Kingdom
17.3. Germany
17.4. France
17.5. Russia
17.6. Italy
17.7. Spain
17.8. United Arab Emirates
17.9. Saudi Arabia
17.10. South Africa
17.11. Denmark
17.12. Netherlands
17.13. Qatar
17.14. Finland
17.15. Sweden
17.16. Nigeria
17.17. Egypt
17.18. Turkey
17.19. Israel
17.20. Norway
17.21. Poland
17.22. Switzerland
18. Asia-Pacific mRNA Synthesis & Manufacturing Market
18.1. Introduction
18.2. China
18.3. India
18.4. Japan
18.5. Australia
18.6. South Korea
18.7. Indonesia
18.8. Thailand
18.9. Philippines
18.10. Malaysia
18.11. Singapore
18.12. Vietnam
18.13. Taiwan
19. Competitive Landscape
19.1. Market Share Analysis, 2024
19.2. FPNV Positioning Matrix, 2024
19.3. Competitive Analysis
19.3.1. Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories Limited
19.3.2. Bio-Synthesis Inc.
19.3.3. Creative Biogene
19.3.4. Creative Biolabs
19.3.5. Croyez Bioscience Co., Ltd.
19.3.6. Danaher Corporation
19.3.7. FUJIFILM Wako Pure Chemical Corporation
19.3.8. Genewiz by Azenta Life Sciences
19.3.9. GenScript Biotech Corporation
19.3.10. Jena Bioscience GmbH by Enzo Biochem Inc.
19.3.11. Lonza Group Ltd.
19.3.12. Merck KGaA
19.3.13. New England Biolabs, Inc.
19.3.14. PackGene Biotech, Inc.
19.3.15. Promega Corporation
19.3.16. Samsung Biologics Co., Ltd.
19.3.17. Sartorius AG
19.3.18. ST Pharm
19.3.19. System Biosciences, LLC
19.3.20. Takara Bio Inc.
19.3.21. Telesis Bio Inc.
19.3.22. Thermo Fisher Scientific Inc.
19.3.23. TriLink BioTechnologies LLC by Maravai Intermediate Holdings, LLC
19.3.24. WuXi Biologics (Cayman) Inc
20. ResearchAI
21. ResearchStatistics
22. ResearchContacts
23. ResearchArticles
24. Appendix
List of Figures
FIGURE 1. MRNA SYNTHESIS & MANUFACTURING MARKET MULTI-CURRENCY
FIGURE 2. MRNA SYNTHESIS & MANUFACTURING MARKET MULTI-LANGUAGE
FIGURE 3. MRNA SYNTHESIS & MANUFACTURING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 16. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 18. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 22. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 24. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 26. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 28. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. MRNA SYNTHESIS & MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 32. MRNA SYNTHESIS & MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. MRNA SYNTHESIS & MANUFACTURING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CAPPING & TAILING, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY FORMULATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN SILICO DESIGN, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MODIFICATION & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PURIFICATION & QUALITY CONTROL, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STORAGE & DISTRIBUTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TEMPLATE DNA PREPARATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CLIENT-SPECIFIC MRNA ORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TAILORED RESEARCH SPECIFICATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CATALOGED MRNA VARIANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY OFF-THE-SHELF MRNA SELECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ADVANCED LNP FORMULATION TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ENZYMATIC CAPPING & CAP ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GENETIC ENGINEERING & CODON OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VITRO TRANSCRIPTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PLASMID DNA TEMPLATE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY POLYADENYLATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY RNA PURIFICATION TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY LAB SCALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PILOT SCALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VITRO SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY IN VIVO SYNTHESIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PROPHYLACTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTIC VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY HUMAN USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VETERINARY USE, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY GOVERNMENT RESEARCH BODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY UNIVERSITY LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 86. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 87. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 88. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 89. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 90. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 91. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 92. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 93. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 95. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 96. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 97. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. CANADA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 99. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 100. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 101. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 102. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 103. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 104. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 105. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 106. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 107. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 108. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 109. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 110. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. MEXICO MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 125. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 126. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 127. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 141. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 152. UNITED KINGDOM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 153. UNITED KINGDOM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 154. UNITED KINGDOM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 155. UNITED KINGDOM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 156. UNITED KINGDOM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 165. GERMANY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 166. GERMANY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 167. GERMANY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 168. GERMANY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 169. GERMANY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 170. GERMANY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 171. GERMANY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 172. GERMANY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 173. GERMANY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 174. GERMANY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 175. GERMANY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 176. GERMANY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 177. GERMANY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 178. FRANCE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 179. FRANCE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 180. FRANCE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 181. FRANCE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 182. FRANCE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 183. FRANCE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 184. FRANCE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 185. FRANCE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 186. FRANCE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 187. FRANCE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 188. FRANCE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 189. FRANCE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 190. FRANCE MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 204. ITALY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 205. ITALY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 206. ITALY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 207. ITALY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 208. ITALY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 209. ITALY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 210. ITALY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 211. ITALY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 212. ITALY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 213. ITALY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 214. ITALY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 215. ITALY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 216. ITALY MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 217. SPAIN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 218. SPAIN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 219. SPAIN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 220. SPAIN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 221. SPAIN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 222. SPAIN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 223. SPAIN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 224. SPAIN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 225. SPAIN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 226. SPAIN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 227. SPAIN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 228. SPAIN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. SPAIN MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 234. UNITED ARAB EMIRATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 235. UNITED ARAB EMIRATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 236. UNITED ARAB EMIRATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 237. UNITED ARAB EMIRATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 238. UNITED ARAB EMIRATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 239. UNITED ARAB EMIRATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 240. UNITED ARAB EMIRATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 243. SAUDI ARABIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 244. SAUDI ARABIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 245. SAUDI ARABIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 252. SAUDI ARABIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 254. SAUDI ARABIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 258. SOUTH AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 259. SOUTH AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 260. SOUTH AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 261. SOUTH AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 262. SOUTH AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 263. SOUTH AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 264. SOUTH AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 265. SOUTH AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 266. SOUTH AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 268. SOUTH AFRICA MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 269. DENMARK MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 270. DENMARK MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 271. DENMARK MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 272. DENMARK MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 273. DENMARK MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 274. DENMARK MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 275. DENMARK MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 276. DENMARK MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 277. DENMARK MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 278. DENMARK MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 279. DENMARK MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 280. DENMARK MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 281. DENMARK MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 282. NETHERLANDS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 283. NETHERLANDS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 284. NETHERLANDS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD MILLION)
TABLE 285. NETHERLANDS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY STANDARD MRNA PRODUCTION, 2018-2030 (USD MILLION)
TABLE 286. NETHERLANDS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING PROCESS, 2018-2030 (USD MILLION)
TABLE 287. NETHERLANDS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY MANUFACTURING SCALE, 2018-2030 (USD MILLION)
TABLE 288. NETHERLANDS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 289. NETHERLANDS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 290. NETHERLANDS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
TABLE 291. NETHERLANDS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY VACCINES, 2018-2030 (USD MILLION)
TABLE 292. NETHERLANDS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY USAGE, 2018-2030 (USD MILLION)
TABLE 293. NETHERLANDS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 294. NETHERLANDS MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 295. QATAR MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICES, 2018-2030 (USD MILLION)
TABLE 296. QATAR MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY SERVICE TYPE, 2018-2030 (USD MILLION)
TABLE 297. QATAR MRNA SYNTHESIS & MANUFACTURING MARKET SIZE, BY CUSTOM MRNA SYNTHESIS, 2018-2030 (USD

Companies Mentioned

The companies profiled in this mRNA Synthesis & Manufacturing market report include:
  • Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories Limited
  • Bio-Synthesis Inc.
  • Creative Biogene
  • Creative Biolabs
  • Croyez Bioscience Co., Ltd.
  • Danaher Corporation
  • FUJIFILM Wako Pure Chemical Corporation
  • Genewiz by Azenta Life Sciences
  • GenScript Biotech Corporation
  • Jena Bioscience GmbH by Enzo Biochem Inc.
  • Lonza Group Ltd.
  • Merck KGaA
  • New England Biolabs, Inc.
  • PackGene Biotech, Inc.
  • Promega Corporation
  • Samsung Biologics Co., Ltd.
  • Sartorius AG
  • ST Pharm
  • System Biosciences, LLC
  • Takara Bio Inc.
  • Telesis Bio Inc.
  • Thermo Fisher Scientific Inc.
  • TriLink BioTechnologies LLC by Maravai Intermediate Holdings, LLC
  • WuXi Biologics (Cayman) Inc

Methodology

Loading
LOADING...

Table Information